BASF Pharma Ingredients and Services
Soluplus® delivers new levels of solubility and bioavailability for poorly soluble APIs. Exhibiting high flowability and extrudability, Soluplus® shows superior performance in forming solid solutions, especially in hot-melt extrusion processes.
Soluplus® the solid solution is an innovative excipient that enables new levels of solubility and bioavailability for poorly soluble active ingredients. Developed specifically for solid solutions, this easy-to-process polymer produces a significant improvement in API release.
Thanks to its high flowability and excellent extrudability, Soluplus® exhibits superior performance in forming solid solutions, especially in hot-melt extrusion processes. These solid solutions make the active pharmaceutical ingredient available in a dissolved state, leading to improved bioavailability once in the body. As a result, the polymer is opening new doors in the research and development of innovative pharmaceuticals.
Soluplus® is not limited to solid solutions formed via hot-melt extrusion, but can also be used as a matrix former in spray-drying processes. In addition, it can be deployed as a binder in wet or dry granulation and in drug layering.
A wide range of toxicological studies have been performed on Soluplus®, and the safety of the product has been comprehensively documented.
BASF Pharma Ingredients and Serviceswww.soluplus.compharma-ingredients@basf.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
